Abstract
Background The second wave of COVID-19 is affecting most of the world. The scenario is very grim in India where the daily count on April 15, 2021 itself is double of the first peak. The epidemic evolution there is quite complex due to regional inhomogeneities. In this paper, we characterize the virus spread in the ongoing second wave in India, as well as study the dynamical evolution of epidemic from the beginning of the pandemic.
Methods Variations in the effective reproduction number (Rt) in India are taken as a quantifiable measure of the virus transmissibility and are compared with those of other countries where the second wave is already over. Further, characteristics of COVID-19 spread are analyzed for Indian states by estimating test positivity and case fatality rates. Finally, forecasts and actionable inputs are provided based on mathematical and epidemiological models.
Results Effective reproduction number for almost every state in India has value greater than 1 indicating the presence of the second wave. An exponential fit on recent data indicates that the infection rate is much higher than the first wave however the case fatality rate is lower. Preliminary estimates with the SIR model suggest the peak for the second wave to occur in mid-May 2021 with daily count exceeding 0.35 million.
Conclusions The spread of the second wave is much faster than the first wave. Hence, quick and effective administrative intervention is needed to arrest the rapid growth of the epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This material is based partly upon work supported by a SERB MATRICS project SERB/F/847/2020-2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work does not need any approval of the IRB/oversight body.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: aryans{at}iitk.ac.in, E-mail: mkv{at}iitk.ac.in
Data Availability
The data included in the study are publicly available.
